中国P站

Therapeutic drug monitoring; Tacrolimus; Renal transplant; Immunosuppressive therapy; Dose optimization; Pharmacokinetics; Drug level monitoring; Graft survival; Interindividual variability; Clinical pharmacology

Introduction

Tacrolimus, a calcineurin inhibitor, is a cornerstone of immunosuppressive therapy in renal transplant recipients. Despite its efficacy in preventing graft rejection, tacrolimus has a narrow therapeutic index and exhibits significant interindividual variability in pharmacokinetics. Under-dosing may lead to graft rejection, while overexposure increases the risk of nephrotoxicity, infections, and other complications [1-5]. Therefore, Therapeutic Drug Monitoring (TDM) is essential to ensure optimal tacrolimus exposure and improve patient outcomes. By measuring drug concentrations in blood and adjusting doses accordingly, clinicians can personalize therapy and reduce the risks of both rejection and toxicity. This study investigates the role of TDM in tacrolimus dose optimization in renal transplant patients, emphasizing the impact on graft survival and long-term renal function [6-10].

Discussion

TDM is routinely used in transplant medicine to maintain tacrolimus levels within a defined therapeutic range. Factors influencing tacrolimus pharmacokinetics include genetic polymorphisms (especially CYP3A5), age, ethnicity, drug interactions, and organ function. CYP3A5 expressers often require higher tacrolimus doses, and genotyping can guide initial dosing. Trough level monitoring (C0) remains the standard, but recent studies suggest that area under the curve (AUC) monitoring may offer better correlation with drug efficacy and toxicity. Dose adjustments based on TDM have led to improved graft outcomes and fewer adverse events. Technological advances, such as microsampling and LC-MS/MS analysis, have enhanced the accuracy and accessibility of TDM. Despite its proven benefits, challenges include delayed lab turnaround, variability in target levels across centers, and the need for clinician expertise in interpretation. Integrating TDM with pharmacogenomics could further refine personalized immunosuppressive regimens.

Conclusion

TDM plays a critical role in optimizing tacrolimus therapy for renal transplant recipients. It enhances the safety and effectiveness of immunosuppression by tailoring dosing to individual pharmacokinetics. As precision medicine evolves, combining TDM with pharmacogenetic insights will enable more refined and patient-specific treatment approaches, ultimately improving long-term graft survival and reducing complications.

References

1. Martinon F (1993) . Eur J Immunol 23: 1719-1722.

   , ,

2. Krienke C (2021) . Science 371: 145-153.

   , ,

3. Richner JM (2017) . Cell 168: 1114-1125.

   , ,

4. Chahal JS (2016) Proc Natl Acad Sci USA 113: E4133-E4142.

   , ,

5. Alberer M (2017) Lancet 390: 1511-1520.

   , ,

6. Rojas LA (2023) Nature 618: 144-150.

   , ,

7. Coffman RL, Sher A, Seder RA (2010) Immunity 33: 492-503.

   , ,

8. Arunachalam PS (2021) . Nature 594: 253-258.

   , ,

9. Andreano E (2023) . Nat Commun 14: 53.

   , ,

10. Mallory K (2021) . NPJ Vaccines. 6: 84.

    , ,